Decoy Therapeutics Inc. (DCOY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Decoy Therapeutics Inc. (DCOY) has a cash flow conversion efficiency ratio of -0.614x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.65 Million) by net assets ($4.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Decoy Therapeutics Inc. (DCOY) market capitalisation for the company's overall valuation and market capitalisation.
Decoy Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Decoy Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Decoy Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Decoy Therapeutics Inc. ranked by their cash flow conversion efficiency. See Decoy Therapeutics Inc. (DCOY) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
M N C Wireless Bhd
KLSE:0103
|
0.187x |
|
SOLAI Limited
NYSE:SLAIY
|
N/A |
|
Farmmi Inc
NASDAQ:FAMI
|
0.306x |
|
Medesis Pharma SA
PA:ALMDP
|
N/A |
|
Ranchero Gold Corp
V:RNCH
|
-1.403x |
|
Spectra Inc.
V:SSA
|
-0.026x |
|
France Tourisme Immobilier SA
PA:MLFTI
|
N/A |
|
Hadasit Bio
TA:HDST
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Decoy Therapeutics Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Decoy Therapeutics Inc. from 2014 to 2025. View Decoy Therapeutics Inc. (DCOY) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.89 Million | $-4.83 Million | -0.820x | +72.62% |
| 2024-12-31 | $1.51 Million | $-4.53 Million | -2.994x | -23.21% |
| 2023-12-31 | $5.29 Million | $-12.85 Million | -2.430x | -43.39% |
| 2022-12-31 | $10.38 Million | $-17.60 Million | -1.694x | -543.23% |
| 2021-12-31 | $38.72 Million | $-10.20 Million | -0.263x | +43.39% |
| 2020-12-31 | $22.16 Million | $-10.31 Million | -0.465x | +57.48% |
| 2019-12-31 | $10.58 Million | $-11.58 Million | -1.094x | +56.95% |
| 2018-12-31 | $9.28 Million | $-23.60 Million | -2.542x | -166.91% |
| 2017-12-31 | $29.11 Million | $-27.72 Million | -0.952x | -76.27% |
| 2016-12-31 | $59.32 Million | $-32.05 Million | -0.540x | -140.12% |
| 2015-12-31 | $92.19 Million | $-20.75 Million | -0.225x | -121.23% |
| 2014-12-31 | $-6.54 Million | $-6.93 Million | 1.060x | -- |
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverage… Read more